Array Announces Agreement To Acquire ENCORAFENIB (LGX818)

- Array to receive global rights from Novartis to innovative BRAF inhibitor -
- Novartis to conduct and/or substantially fund ongoing clinical studies, including COLUMBUS -
- Agreement subject to Novartis-GSK transaction close -
- Conference call to discuss transaction on January 23, 2015 at 9:00 am Eastern Time -

BOULDER, Colo., Jan. 23, 2015 -- Array BioPharma Inc. (ARRY) today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.  This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement.

Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001

Egalet-001 Met Primary Endpoint of Reduced Drug Liking Compared to MS Contin(R)

WAYNE, Pa., Jan. 22, 2015 -- Egalet Corporation (EGLT) ("Egalet") today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The clinical HAL study demonstrated that in nondependent, recreational opioid users, the abuse potential of manipulated Egalet-001 taken orally was significantly lower than that for manipulated MS Contin (morphine sulfate controlled-release).

Theralase Identifies Lead Photo Dynamic Compound for Human Clinical Trials

Toronto, Ontario -  January 15, 2015 / Theralase Technologies Inc. ("Theralase") (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that it has identified its lead Photo Dynamic Compound ("PDC") that it plans to enter into a Health Canada Clinical Trial Application ("CTA") / Food and Drug Administration ("FDA") Investigational New Drug ("IND") Application for the destruction of Non Muscle Invasive Bladder Cancer ("NMIBC") in 2015.

The lead PDC has been identified to be TLD-1433, a Ruthenium based PDC that has demonstrated a high Therapeutic Ratio, which has the highest overall performance in the green and red laser light spectrums for multiple cancer cell lines, including glioma (primary brain tumours that originate from the supportive cells of the brain) and bladder cancer.

CorMedix Inc. Receives Fast Track Designation for Neutrolin®

BRIDGEWATER, N.J., Jan. 15, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) granted its request for Fast Track designation of its lead product candidate, Neutrolin^® Catheter Lock Solution, pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA).  CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.